Steno Raises $49M to Scale AI Litigation Support
- •Steno raises $49 million Series C, bringing total capital to $150 million for legal AI expansion.
- •Investment targets AmLaw 200 law firms and accelerates development of the AI-powered Transcript Genius platform.
- •The system employs Retrieval-Augmented Generation to provide attorneys with accurate, data-grounded summaries of testimony.
Steno has announced a significant $49 million Series C equity round to transform how legal professionals interact with testimony. This fresh capital, led by Savano Capital Partners with participation from First Round Capital, brings the company’s total funding to $150 million. The company aims to use these resources to penetrate the AmLaw 200—the top-grossing US law firms—while tripling its investment in specialized litigation technology.
The core of Steno's growth lies in its strategic pivot from traditional court reporting to a tech-enabled ecosystem. Their flagship tool, Transcript Genius, utilizes advanced language models to analyze legal transcripts and depositions. By integrating AI directly into the litigation workflow, the tool helps attorneys identify key testimony and summarize complex case data more efficiently than manual review.
CEO Greg Hong explains that Steno’s hybrid model—operating as both a service provider and a software developer—provides a distinct edge. Unlike software-only competitors, Steno manages the entire lifecycle of legal data, from the initial capture of testimony to the final analysis. This approach allows for specialized features that address the specific friction points of high-stakes legal proceedings.
Steno is now implementing Retrieval-Augmented Generation (RAG) to ensure that every AI summary is perfectly grounded in the provided evidence. The goal is to build a unified platform where data-informed AI and human expertise work in tandem. This reflects a broader trend in the industry: the transition from standalone chatbots to comprehensive platforms that manage the heavy lifting of case strategy.